Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease.

ABSTRACT:

Objectives

Growing evidence argues for a relationship between liver and bone metabolisms. Sclerostin is a secreted glycoprotein and could antagonize osteoblast-mediated bone formation. Previous studies indicated that circulating sclerostin levels may be associated with metabolic parameters with inconsistent results. This study was designed to evaluate serum sclerostin in patients with or without nonalcoholic fatty liver disease (NAFLD) and to analyze its relationship with metabolic parameters in different populations.

Methods

A cross-sectional study was designed and 168 NAFLD subjects and 85 control subjects were included in this study. Serum sclerostin and metabolic parameters were measured. Mouse models of NAFLD were also induced by high-fat diet. Bone structural parameter

SUBMITTER: Zhou F 

PROVIDER: S-EPMC8374147 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature